News | Structural Heart | July 03, 2024

Cedars-Sinai Cardiologist Leads the American Society of Transplantation

Jon Kobashigawa, MD, steps into presidency of the largest transplant organization in North America

Jon Kobashigawa, MD, of the Smidt Heart Institute at Cedars-Sinai, is an expert in heart transplantation, heart failure, and other complex cardiac conditions

Jon Kobashigawa, MD, of the Smidt Heart Institute at Cedars-Sinai, is an expert in heart transplantation, heart failure, and other complex cardiac conditions. Photo by Cedars-Sinai.


July 3, 2024 — Jon Kobashigawa, MD, director of the Heart Transplant Program in the Department of Cardiology in the Smidt Heart Institute at Cedars-Sinai, has assumed the top volunteer leadership position of the American Society of Transplantation.

As of June, Kobashigawa became president of the society, leading an organization of more than 5,000 clinicians and other healthcare professionals who work in the field of organ transplantation. His responsibilities include working to ensure the organization fulfills its strategic vision of advancing the field of transplantation and improving patient care by promoting research, education, advocacy, organ donation and service to the community.

Kobashigawa will also represent the American Society of Transplantation in discussions with government agencies and policymakers about organ transplant legislation.

“Dr. Kobashigawa’s experience and passion make him the ideal person to serve as a national and international voice in all matters related to organ transplantation,” said Eduardo Marbán, MD, PhD, executive director of the Smidt Heart Institute and the Mark S. Siegel Family Foundation Distinguished Professor. “He has already advanced this field greatly through his clinical work and scientific discoveries and continues to be a strong advocate for standardizing decisions and processes related to transplantation.”

Kobashigawa was instrumental in expanding the Comprehensive Transplant Program at Cedars-Sinai, one of the largest transplant programs in the world.

“Dr. Kobashigawa was instrumental in the development of our world-renowned medical and surgical program, known for changing the lives of patients previously told they were out of options,” said Christine Albert, MD, MPH, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology.

An expert in diagnosing heart failure, Kobashigawa also is director of the Advanced Heart Disease Division in the Smidt Heart Institute. He evaluates patients for heart transplants and medically manages their health before and after transplantation. Kobashigawa has been part of seminal research studies that have led to the use of novel therapies to prevent and treat organ rejection.  

In addition to his clinical and research expertise, Kobashigawa is known for developing standards for the field of transplantation. He has organized 17 national and international conferences that have led to guidelines on critical issues such as organ allocation, organ failure diagnosis and organ rejection.

Kobashigawa has held several leadership positions in transplantation organizations. He is a past president of the International Society of Heart and Lung Transplantation and past chair of the American College of Cardiology/American Heart Association Committee on Heart Failure and Transplantation. He also has served as a member of several United Network for Organ Sharing committees. He has published more than 480 peer-reviewed research publications and was recognized with the 2023 Lifetime Achievement Award from the International Society for Heart and Lung Transplantation.

“It is an honor to lead the American Society of Transplantation, a prestigious organization with which I have long been involved,” said Kobashigawa, the DSL/Thomas D. Gordon Chair in Heart Transplantation Medicine at Cedars-Sinai. “I look forward to working with esteemed colleagues to advance transplantation policy, research and public education.”

For more information: www.cedars-sinai.org


Related Content

News | Cardiovascular Business

July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing ...

Home July 29, 2024
Home
News | Cardiovascular Business

July 18, 2024 — Circle Cardiovascular Imaging, a developer of artificial intelligence (AI)-driven cardiovascular imaging ...

Home July 18, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Guidehealth, an artificial intelligence (AI)-enabled healthcare services company, has announced a ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Edwards Lifesciences announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 11, 2024 — Medical device company R3 Vascular Inc., developer of novel, best-in-class bioresorbable scaffolds for ...

Home July 11, 2024
Home
News | Cardiovascular Business

July 9, 2024 — Disparities in cardiovascular disease outcomes between urban and rural areas continue to widen, yet ...

Home July 09, 2024
Home
Feature | Cardiovascular Business

The DAIC team wishes you a safe and happy 4th of July!

Home July 04, 2024
Home
News | Cardiovascular Business

July 3, 2024 — Over the past decade, 342 cardiology clinics have been acquired by private equity firms, with over 94% of ...

Home July 03, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

From FDA approvals to new clinical trials, here is a look at DAIC's top-read content during the month of June: 1 ...

Home July 02, 2024
Home
News | Cardiovascular Business

July 1, 2024 — CVRx, Inc., a commercial-stage medical device company, announced three additions to its senior leadership ...

Home July 01, 2024
Home
Subscribe Now